Clinical trials: DM
Type 2 Diabetes Mellitus
Diabetes Mellitus Type 2 Basal Insulin Dosing Requirements Study
The main purpose of this study is to determine the number of daily basal insulin rate changes that are needed to achieve short-term near normal glucose control in insulin pump patients with type 2 diabetes
- Trial name
- NCT00874809
- Testing
- CGMS with an insulin pump using rapid acting insulin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Diabetes Care Center
Type 2 Diabetes Mellitus
Study Comparing Efficacy and Safety of Amaryl M and Metformin Uptitraion to Type 2 DM
The aim of this study is to compare the efficacy and safety of early combination therapy with Amaryl M with that of uptitration of metformin monotherapy in patients with type 2 DM inadequately controlled by prior monotherapy with…
- Trial name
- NCT00612144
- Testing
- Glimepiride/metformin fixed combination, Metformin HCl
- Where
- South Korea
- Volunteers
- 192 people
- Sponsor
- Handok Inc.
Hypertension, Type 2 Diabetes Mellitus
A Comparison of Indapamide SR 1.5 mg With HCTZ 25 mg, in Combination With an ACE-inhibitor, in Patients With Mild to Moderate AHT and Type 2 DM
The aim of this study is to evaluate the effects of indapamide SR 1.5 mg on blood pressure, blood tests (glucose metabolism, lipids, minerals, and uric acid), cardiac function, endothelial and arterial function, by comparison…
- Trial name
- AISHA (NCT00980187)
- Testing
- Hydrochlorothiazide, Indapamide
- Where
- Romania
- Volunteers
- 56 people
- Sponsor
- LaborMed Pharma S.A.
Dermatomyositis Interstitial Lung Disease (Dm-ILD)
Efficacy and Safety of Pirfenidone in Patient With Dermatomyositis Interstitial Lung Disease (Dm-ILD)
The purpose of this study is to evaluate the efficacy and safety of pirfenidone in subjects with dermatomyositis interstitial lung disease
- Trial name
- NCT03857854
- Testing
- Pirfenidone
- Where
- China
- Volunteers
- 152 people
- Sponsor
- Beijing Continent Pharmaceutical Co, Ltd.
Advanced Cancer, Brain Metastases
DM-CHOC-PEN for Brain Tumors in AYA Subjects
4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) is a polychlorinated pyridyl cholesterol carbonate that is lipophilic, electrically neural, crosses the blood brain barrier (BBB), ability to localize in intracranial…
- Trial name
- NCT03668847
- Testing
- DM-CHOC-PEN
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- DEKK-TEC, Inc.
Dermatomyositis
Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy)
Prospective, Double-blind, Randomized, Placebo-Controlled Phase III Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis ("ProDERM study")
- Trial name
- IIM (NCT02728752)
- Testing
- Octagam 10%
- Where
- 37 sites in United States, Canada and 8 more
- Volunteers
- 95 people
- Sponsor
- Octapharma
DM1, Muscular Dystrophies
Extension of AOC 1001-CS1 (MARINA) Study in Adult Myotonic Dystrophy Type 1 (DM1) Patients
AOC 1001-CS2 (MARINA-OLE) (NCT05479981) is a Phase 2 extension of the AOC 1001-CS1 (MARINA) (NCT05027269) study to evaluate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of multiple-doses of AOC 1001…
- Conditions
- DM1, Muscular Dystrophies, Myotonic Dystrophy, Myotonic Dystrophy 1
- Trial name
- MARINA-OLE (NCT05479981)
- Testing
- AOC 1001
- Where
- 8 sites in United States
- Volunteers
- 37 people
- Sponsor
- Avidity Biosciences, Inc.
Diabetes (DM)
A Study to Investigate a Transdermal Continuous Glucose Monitoring System in Diabetic Patients for a Period of 28 Days
Single-centre, open label (unblinded). A maximum of 48 patients will be enrolled in 4 Cohorts of 10 patients and 2 potential replacements each. Diabetic patients (type 1 and 2).
- Trial name
- FiberSense (NCT06868043)
- Testing
- FiberSense System
- Where
- Germany
- Volunteers
- 10 people
- Sponsor
- EyeSense GmbH
Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP)
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
This Phase 1b basket trial will investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and preliminary efficacy of RAY121, a inhibitor of classical complement pathway, after multiple dose…
- Conditions
- Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP), Behçet's Syndrome (BS), Dermatomyositis (DM)
- Trial name
- NCT06371417
- Testing
- RAY121
- Where
- 77 sites in United States, Australia and 18 more
- Volunteers
- 144 people
- Sponsor
- Chugai Pharmaceutical
Peripheral Arterial Disease (PAD), Diabetes Mellitus (DM)
The Efficacy and Safety of REX-001 to Treat Ischemic Ulcers in Subjects With CLI Rutherford Category 5 and DM
This trial is a pivotal, placebo-controlled, double-blind, parallel-group, adaptive trial conducted in subjects with DM and CLI Rutherford Category 5.
- Conditions
- Peripheral Arterial Disease (PAD), Diabetes Mellitus (DM), Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT03174522
- Testing
- REX-001
- Where
- 15 sites in Czechia, Hungary and 4 more
- Volunteers
- 49 people
- Sponsor
- Ixaka Ltd
Diabetes Mellitus, Non-Insulin-Dependent
The Efficacy and Safety Study in Patients With Type 2 Diabetes Mellitus
The efficacy and safety study of saxagliptin 5mg, once daily for 24 weeks in patients with type 2 diabetes mellitus.
- Trial name
- SUNSHINE (NCT01608724)
- Testing
- Saxagliptin
- Where
- 37 sites in China
- Volunteers
- 2,165 people
- Sponsor
- AstraZeneca
Epidermolysis Bullosa Simplex
Safety and Efficacy of Topical TolaSure Targeting Aggregated Mutant Keratin in Severe Epidermolysis Bullosa Simplex
TolaSure is a topical gel for the promotion of accelerated wound healing. This Phase I study will assess the safety, tolerability, and clinical effects of TolaSure when applied to wounded skin areas of patients diagnosed with…
- Trial name
- TAMES (NCT05062070)
- Testing
- TolaSure Topical Gel, Vehicle Topical Gel
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- BioMendics, LLC
Diabetics Mellitus Type 1, Diabetes Mellitus Type 2
Testing the Effect of the InsuPad Device in Daily Life Conditions
This is the test protocol for the InsuPad device. The aim of the study is to show economical benefit when using the InsuPad device, by testing the effect of the InsuPad device on reducing injected insulin dose while keeping the…
- Trial name
- NCT01594801
- Testing
- InsuPad
- Where
- 9 sites in Germany
- Volunteers
- 145 people
- Sponsor
- Insuline Medical Ltd.
Diabetes (DM)
RIGHTEST iFree 2 CGM System for Glycemic Control in Adults With Diabetes Mellitus
The goal of this clinical trial is to find out whether using a real-time continuous glucose monitoring (CGM) system can improve daily blood sugar control compared with usual self-monitoring of blood glucose (SMBG; finger-stick…
- Trial name
- NCT07889375
- Testing
- Continuous Glucose Monitoring (CGM), Self-monitoring of blood glucose (SMBG)
- Where
- Taiwan
- Volunteers
- 324 people
- Sponsor
- Bionime Corporation
Diabetes Type 2, Diabetes
Study Evaluating the Metabolic Effects of pulsENDO Therapy in Adults With Type 2 Diabetes
This is a prospective, multicenter, randomized, double-blind, sham-controlled, adaptive study evaluating the pulsENDO system in individuals with type 2 diabetes (T2D) inadequately controlled on non-insulin glucose-lowering…
- Conditions
- Diabetes Type 2, Diabetes, Diabetes (DM), Weight Change
- Trial name
- pulsENDO (NCT07768631)
- Testing
- pulsENDO Therapy
- Volunteers
- 320 people
- Sponsor
- Endogenex, Inc.
DM1, Myotonic Dystrophy 1
Study of AOC 1001 in Adult Myotonic Dystrophy Type 1 (DM1) Patients
AOC 1001-CS1 is a randomized, double-blind, placebo-controlled, Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple-doses of AOC 1001 Administered Intravenously to…
- Conditions
- DM1, Myotonic Dystrophy 1, Myotonic Dystrophy, Myotonic Dystrophy Type 1 (DM1)
- Trial name
- MARINA (NCT05027269)
- Testing
- AOC 1001
- Where
- 8 sites in United States
- Volunteers
- 39 people
- Sponsor
- Avidity Biosciences, Inc.
Diabetes Mellitus, Type 2 DM
Glycemic Control With Triple Pathway Approach Through Empagliflozin, Linagliptin and Metformin Combination
The efficacy and safety of a triple-pill combination therapy for advanced type 2 diabetes care. The study aims to assess the impact of 3 Oral Anti Diabetic (OAD) drugs on metabolic control, patient compliance, weight management…
- Trial name
- GLYCO-3P (NCT06862739)
- Testing
- Empagliflozin+Linagliptin+Metformin
- Where
- 2 sites in Pakistan
- Volunteers
- 800 people
- Sponsor
- Nabiqasim Industries (Pvt) Ltd
Type 2 Diabetes, Type 2 Diabetes Mellitus (T2DM)
Embecta AID System in Adults With Type 2 Diabetes
This is a multi-center, randomized control study that will evaluate the safety and effectiveness of the embecta Automated Insulin Delivery System in adults with Type 2 diabetes requiring insulin therapy
- Conditions
- Type 2 Diabetes, Type 2 Diabetes Mellitus (T2DM), Type 2 DM, T2DM With Inadequate Glycemic Control
- Trial name
- EMBRACE-T2D (NCT06692153)
- Testing
- An AID System., Standard of Care (SC)
- Where
- 9 sites in United States
- Sponsor
- Embecta Corp.
Type 2 Diabetes Mellitus
Effects of Gemigliptin Versus Sitagliptin or Glimepiride With Metformin on Glucose Variability(MAGE, Glucose SD) Patients With Type 2 DM(STABLE Study)
To compare efficacy and safety of initial combination therapy of Gemigliptin versus Sitagliptin or Glimepiride with Metformin on Glucose Variability(MAGE, Glucose SD) in Patients With Type 2 Diabetes Mellitus.
- Trial name
- STABLE (NCT01890629)
- Testing
- Gemigliptin + Metformin / Sitagliptin + Metformin / Glimepiride + Metformin
- Where
- South Korea
- Volunteers
- 69 people
- Sponsor
- LG Life Sciences
Diabetes Mellitus, Type 1
TRX4 Monoclonal Antibody in Type 1 Diabetes (T1 DM)
The purpose of this study is to optimize several multi-dose regimens of otelixizumab, determine the highest biologically active dose, evaluate biomarkers and surrogates of efficacy, and to evaluate the effects of each multi-dose…
- Trial name
- TTEDD (NCT00451321)
- Testing
- Otelixizumab
- Where
- 17 sites in United States, Canada
- Volunteers
- 88 people
- Sponsor
- GlaxoSmithKline